---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-150323"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:27:12.873266+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies holds 2024 annual meeting; directors elected and auditor ratified

## Summary
- Shareholders elect Sean Stalfort and Alison Long as directors until 2027.
- Deloitte & Touche LLP ratified as independent auditor for FY2024.
- Approximately 80% of outstanding shares (149.6M of 187M) were represented at the meeting.
- Director votes: Stalfort 131.8M for, 287.6K withheld; Long 132.0M for, 77.5K withheld.
- Auditor ratification: 149.5M for, 60.4K against, 100.5K abstained; no broker non-votes.

## SEC filing metadata
- accession: 0001193125-24-150323
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524150323/0001193125-24-150323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524150323/d805768d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-150323
- JSON: https://secwatch.observer/filing/0001193125-24-150323.json
- Plain text: https://secwatch.observer/filing/0001193125-24-150323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.